The earnings call reflected a generally positive outlook, with strong order intake growth and improvements in adjusted EBITA margin driven by innovation and productivity measures. However, challenges such as the decline in Connected Care sales, subdued performance in China, and the impact of tariffs were noted. Despite these challenges, the Company has increased its adjusted EBITA margin and free cash flow outlook, indicating confidence in its ongoing strategies.

Company Guidance -

Q3 2025

During the second quarter of 2025, Philips reported a range of positive metrics, showcasing robust performance and strategic advancements. Order intake grew by 6%, building on a 9% increase from the previous year, while comparable sales rose by 1%, driven by strong performance in Personal Health. The company achieved a 130 basis point expansion in margins to 12.4%, attributed to innovation and productivity measures. Philips reiterated its full-year comparable sales growth outlook of 1% to 3% and raised its adjusted EBITA margin range to 11.3% to 11.8%, incorporating recent tariff developments. Additionally, Philips expects full-year free cash flow to range between EUR 0.2 billion and EUR 0.4 billion, assuming current tariff levels persist. The company highlighted strong double-digit order intake growth in North America, substantial contributions from Diagnosis & Treatment and Connected Care segments, and successful new innovations, particularly in Image-Guided Therapy and Precision Diagnosis.

Order Intake Growth

Order intake grew 6% in Q2, building on 9% growth from the previous year, with sustained double-digit growth in North America and strong performance across growth geographies.

Adjusted EBITA Margin Improvement

Adjusted EBITA margin increased by 130 basis points to 12.4% in Q2, driven by productivity measures, improved gross margin from innovation, favorable mix effect, and improved operational efficiency.

Strong Performance in Personal Health

All three businesses within Personal Health grew, driven by strong traction from new innovations and enhancements to core products, supported by targeted investments. This was partially offset by a decline in China.

Supply Chain Reliability Improvement

Service levels reached an all-time high of 86% in Q2, an improvement of more than 10 percentage points year-on-year.

Innovation in Image-Guided Therapy

A multiyear nationwide agreement with the Indonesian Ministry of Health will expand access to image-guided therapy using the Azurion platform, highlighting Philips' leadership in minimally invasive procedures.

Koninklijke Philips (PHG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.37 / -	0.338	―	―	―
Jul 29, 2025	2025 (Q2)	0.32 / 0.41	0.324	28.09% (+0.09)
May 06, 2025	2025 (Q1)	0.20 / 0.28	0.269	5.58% (+0.01)
Feb 19, 2025	2024 (Q4)	0.57 / 0.53	0.426	24.88% (+0.11)
Oct 28, 2024	2024 (Q3)	0.44 / 0.34	0.338	0.00% (0.00)
Jul 29, 2024	2024 (Q2)	0.36 / 0.32	0.288	12.50% (+0.04)
Apr 29, 2024	2024 (Q1)	0.29 / 0.27	0.225	19.56% (+0.04)
Jan 29, 2024	2023 (Q4)	0.56 / 0.43	0.413	3.15% (+0.01)
Oct 23, 2023	2023 (Q3)	0.30 / 0.34	0.229	47.60% (+0.11)
Jul 24, 2023	2023 (Q2)	0.28 / 0.29	0.132	118.18% (+0.16)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$25.66	$28.02	+9.20%
May 06, 2025	$24.87	$23.36	-6.07%
Feb 19, 2025	$27.46	$24.30	-11.51%
Oct 28, 2024	$30.72	$25.82	-15.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.